As described in “Ten IT-enabled business trends for the
decade ahead,” I have seen and experienced first-hand what adapting to upcoming
trends entails and how hard it can be for major corporations to adjust,
compared to smaller ones. When I read
this article and “The four global forces breaking all the trends,” I realize
that my organization inside of our IT department is trying to align with most
of the items listed, due to the nature of our business. Ten years ago, there were over 480 Colleagues
in our group and now we are running with 62.
The reason: Adapting to shifting IT trends and understanding the flows
of our business as we grow in other areas of the world and how to connect those
areas together with the technology offerings of today.
I’ve not only weathered the storm of outsourcing, but also
been leading the efforts in Cloud On-Ramp and Automation for Network
Operations. Currently, I am in the
middle of deploying automation (#5 on the list) in my company’s IT Network
Operations Center. With such a vast environment,
spanning the globe, this has proven to be quite difficult. Even more difficult is the ability to automate
across various IT platforms, without a set architecture standard. It is for this reason that I chose to
outsource this effort to a vendor with extensive experience in this space. If I were to try to do this in-house, it
would be a massive effort, costing more than four times the amount of the
outsource, but the “having this in-house” would remove the risk of
relationships with vendors (i.e. if we severe our contract, we would lose the
automation). Given the pricing and
timelines, it made absolute sense to shift the strategy to outsource this
automation effort, which differs from the server space which was in-house
automation.
With our shift to Cloud operations, we are also able to
reach more consumers and broaden our global footprint, engaging more of our
customers and using high-performance compute power for big data analytics. In the pharmaceutical industry, much can be
gained from big data. “Every year, for
example, Pfizer spends $12 million to buy health data from a variety of
sources, including IMS, according to Marc Berger, who oversees the analysis of
anonymized patient data at Pfizer.” [1]
Tanner goes on to say those companies can then use the data
they’ve acquired to help pharmaceutical sales representatives target specific
doctors, hospitals and practices in prescribing their medicine. For example, if a manufacturer of a heart
drug finds a doctor is prescribing a competitors medicine repeatedly, they can
send their rep to that doctor in hopes to persuade the doctor to use their
drug. If they are successful, this can
be a sufficient return on their investment for the purchase of the initial
data.
This ability to foresee the upcoming IT trends and create a
strategy that focuses on shifting our IT operations to these trends, has helped
us maintain a visionary role in the marketplace and I’m glad to be part of all
that we have done and continue to do in this realm of our business.
[1] Tanner, Adam. "How Data Brokers Make Money Off Your
Medical Records." Scientific American. January 11, 2016. Accessed April
25, 2017. https://www.scientificamerican.com/article/how-data-brokers-make-money-off-your-medical-records/.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.